News
VVOS
5.06
+4.33%
0.21
Weekly Report: what happened at VVOS last week (0106-0110)?
Weekly Report · 1d ago
New Strong Buy Stocks for January 8th
NASDAQ · 6d ago
Best Momentum Stocks to Buy for January 8th
Barchart · 01/08 10:18
Weekly Report: what happened at VVOS last week (1230-0103)?
Weekly Report · 01/06 12:16
Weekly Report: what happened at VVOS last week (1223-1227)?
Weekly Report · 12/30/2024 12:07
Morning Movers: Despegar surges following deal to be acquired by Prosus
TipRanks · 12/23/2024 14:00
Vivos to sell 709,220 shares at $4.935 in registered direct offering
TipRanks · 12/23/2024 13:15
Vivos Therapeutics Announces $3.5M Registered Direct Offering Of 709,220 Shares Of Common Stock At $4.935
Benzinga · 12/23/2024 13:04
VIVOS THERAPEUTICS ANNOUNCES $3.5 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 12/23/2024 13:00
Weekly Report: what happened at VVOS last week (1216-1220)?
Weekly Report · 12/23/2024 12:16
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy
NASDAQ · 12/18/2024 17:00
Weekly Report: what happened at VVOS last week (1209-1213)?
Weekly Report · 12/16/2024 12:17
Weekly Report: what happened at VVOS last week (1202-1206)?
Weekly Report · 12/09/2024 12:16
Weekly Report: what happened at VVOS last week (1125-1129)?
Weekly Report · 12/02/2024 12:17
Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/02/2024 11:29
Weekly Report: what happened at VVOS last week (1118-1122)?
Weekly Report · 11/25/2024 12:05
Vivos Therapeutics Price Target Maintained With a $6.60/Share by Ascendiant Capital
Dow Jones · 11/20/2024 09:54
Ascendiant Capital Reiterates Buy on Vivos Therapeutics, Maintains $6.6 Price Target
Benzinga · 11/20/2024 09:44
Vivos Therapeutics Price Target Cut to $6.00/Share From $8.25 by Alliance Global Partners
Dow Jones · 11/19/2024 17:08
Vivos Therapeutics Is Maintained at Buy by Alliance Global Partners
Dow Jones · 11/19/2024 17:08
More
Webull provides a variety of real-time VVOS stock news. You can receive the latest news about Vivos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.